A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Related studies linked through entity extraction aliases.